학술논문

Second Line Treatment with Bruton Tyrosine Kinase Inhibitor (BTKi) or Bcl-2 Inhibitor (Bcl-2i) in Patients with Chronic Lymphocytic Leukemia (CLL): Primary Analysis of the Czech Study Group for CLL (CSCLL)
Document Type
Article
Source
Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p6542-6542, 1p
Subject
Language
ISSN
00064971; 15280020
Abstract
Introduction: